{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:23:10Z","timestamp":1794273790895,"version":"4.9.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiovasc Imaging"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mavacamten, the first selective and reversible cardiac myosin inhibitor (CMI), has been introduced to the clinical arena for the treatment of obstructive hypertrophic cardiomyopathy (HCM). By reducing excessive actin-myosin cross-bridging, this agent decreases myocardial contractility and alleviates the\u00a0dynamic left ventricular outflow tract (LVOT) obstruction in obstructive HCM. In the EXPLORER-HCM trial, mavacamten significantly improved exercise capacity, symptoms, and LVOT pressure gradients, while the VALOR-HCM trial proved it can obviate the need for septal reduction therapy in patients who were deemed to be candidates for septal reduction therapy. Notably, long-term data (MAVA-LTE study) has demonstrated sustained benefits up to 180\u00a0weeks, with\u2009&lt;\u200910% experiencing transient reductions in left ventricular ejection fraction\u2009&lt;\u200950% and only 1.3% of permanent discontinuation rate. Aficamten, a next-generation CMI with a shorter half-life, has also demonstrated comparable efficacy. Reverse remodeling following treatment was noted in both agents. In nonobstructive HCM, preliminary studies (MAVERICK-HCM trial and cohort 4 of REDWOOD-HCM trial) have reported improvements in cardiac serum biomarkers and symptoms. However, the preliminary results from phase 3 trials (ODYSSEY-HCM trial) revealed that primary endpoints were not met in nonobstructive HCM. Regarding safety, both were generally well tolerated. Although an LVEF reduction occurred in some patients, it was reversible with a dose reduction or a short-term drug cessation. These results emphasize careful dosing strategy with regular echocardiographic monitoring. Real-world data have also demonstrated consistent efficacy and safety across varying ethnic groups without new safety signals. CMI is a major advance in HCM management. However, future studies must provide data on hard clinical outcomes, such as heart failure hospitalization or death. Ongoing trials comparing CMI to traditional first-line therapies, such as \u03b2-blockers, will clarify their potential role as an initial therapeutic option.<\/jats:p>","DOI":"10.1186\/s44348-025-00052-7","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T23:26:59Z","timestamp":1751844419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cardiac myosin inhibitors in hypertrophic cardiomyopathy"],"prefix":"10.1186","volume":"33","author":[{"given":"Jaehyun","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Kwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"52_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","volume":"64","author":"BJ Maron","year":"2014","unstructured":"Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS, et al. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol. 2014;64:83\u201399.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR2","doi-asserted-by":"crossref","unstructured":"Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE, et al.\u00a0Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation.\u00a01995;92:785\u20139.","DOI":"10.1161\/01.CIR.92.4.785"},{"key":"52_CR3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR4","doi-asserted-by":"crossref","unstructured":"Braunwald E, Lambrew CT, Rockoff SD, Ross J, Morrow AG.\u00a0Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients.\u00a0Circulation.\u00a01964;30:3\u2013119.","DOI":"10.1161\/01.CIR.29.5S4.IV-3"},{"key":"52_CR5","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/hc4601.097997","volume":"104","author":"I Olivotto","year":"2001","unstructured":"Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104:2517\u201324.","journal-title":"Circulation"},{"key":"52_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0735-1097(01)01727-2","volume":"39","author":"BJ Maron","year":"2002","unstructured":"Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39:301\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR7","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jama.287.10.1308","volume":"287","author":"BJ Maron","year":"2002","unstructured":"Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308\u201320.","journal-title":"JAMA"},{"key":"52_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.036245","volume":"13","author":"S Kwak","year":"2024","unstructured":"Kwak S, Kim J, Park CS, Lee HJ, Park JB, Lee SP, et al. Distinct phenotypic groups and related clinical outcomes in patients with hypertrophic cardiomyopathy. J Am Heart Assoc. 2024;13: e036245.","journal-title":"J Am Heart Assoc"},{"key":"52_CR9","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","volume":"83","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83:2324\u2013405.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR10","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44:3503\u2013626.","journal-title":"Eur Heart J"},{"key":"52_CR11","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","volume":"45","author":"MV Sherrid","year":"2005","unstructured":"Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45:1251\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR12","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med. 2018;379:655\u201368.","journal-title":"N Engl J Med"},{"key":"52_CR13","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","volume":"1","author":"LK Kim","year":"2016","unstructured":"Kim LK, Swaminathan RV, Looser P, Minutello RM, Wong SC, Bergman G, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003\u20132011. JAMA Cardiol. 2016;1:324\u201332.","journal-title":"JAMA Cardiol"},{"key":"52_CR14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.4070\/kcj.2022.0159","volume":"52","author":"HJ Lee","year":"2022","unstructured":"Lee HJ, Kim J, Chang SA, Kim YJ, Kim HK, Lee SC, et al. Major clinical issues in hypertrophic cardiomyopathy. Korean Circ J. 2022;52:563\u201375.","journal-title":"Korean Circ J"},{"key":"52_CR15","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40265-022-01739-7","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Mavacamten: first approval. Drugs. 2022;82:1127\u201335.","journal-title":"Drugs"},{"key":"52_CR16","doi-asserted-by":"publisher","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","volume":"115","author":"RL Anderson","year":"2018","unstructured":"Anderson RL, Trivedi DV, Sarkar SS, Henze M, Ma W, Gong H, et al. Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci U S A. 2018;115:E8143\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"52_CR17","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759\u201369.","journal-title":"Lancet"},{"key":"52_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022;80:95\u2013108.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nsmb.3408","volume":"24","author":"S Nag","year":"2017","unstructured":"Nag S, Trivedi DV, Sarkar SS, Adhikari AS, Sunitha MS, Sutton S, et al. The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations. Nat Struct Mol Biol. 2017;24:525\u201333.","journal-title":"Nat Struct Mol Biol"},{"key":"52_CR20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nrcardio.2016.98","volume":"13","author":"JO Ormerod","year":"2016","unstructured":"Ormerod JO, Frenneaux MP, Sherrid MV. Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy. Nat Rev Cardiol. 2016;13:677\u201387.","journal-title":"Nat Rev Cardiol"},{"key":"52_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351:617\u201321.","journal-title":"Science"},{"key":"52_CR22","doi-asserted-by":"publisher","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","volume":"64","author":"C Chuang","year":"2021","unstructured":"Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, et al. Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem. 2021;64:14142\u201352.","journal-title":"J Med Chem"},{"key":"52_CR23","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","volume":"143","author":"S Saberi","year":"2021","unstructured":"Saberi S, Cardim N, Yamani M, Schulz-Menger J, Li W, Florea V, et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis. Circulation. 2021;143:606\u20138.","journal-title":"Circulation"},{"key":"52_CR24","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","volume":"78","author":"SM Hegde","year":"2021","unstructured":"Hegde SM, Lester SJ, Solomon SD, Michels M, Elliott PM, Nagueh SF, et al. Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021;78:2518\u201332.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR25","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","volume":"45","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P, Or\u0119ziak A, Masri A, Barriales-Villa R, Abraham TP, Owens AT, et al. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2024;45:5071\u201383.","journal-title":"Eur Heart J"},{"key":"52_CR26","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","volume":"147","author":"MY Desai","year":"2023","unstructured":"Desai MY, Owens A, Geske JB, Wolski K, Saberi S, Wang A, et al. Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks. Circulation. 2023;147:850\u201363.","journal-title":"Circulation"},{"key":"52_CR27","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","volume":"8","author":"MY Desai","year":"2023","unstructured":"Desai MY, Owens A, Wolski K, Geske JB, Saberi S, Wang A, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial. JAMA Cardiol. 2023;8:968\u201377.","journal-title":"JAMA Cardiol"},{"key":"52_CR28","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","volume":"151","author":"MY Desai","year":"2025","unstructured":"Desai MY, Wolski K, Owens A, Geske JB, Saberi S, Wang A, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM. Circulation. 2025;151:1378\u201390.","journal-title":"Circulation"},{"key":"52_CR29","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","volume":"8","author":"Z Tian","year":"2023","unstructured":"Tian Z, Li L, Li X, Wang J, Zhang Q, Li Z, et al. Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial. JAMA Cardiol. 2023;8:957\u201365.","journal-title":"JAMA Cardiol"},{"key":"52_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4070\/kcj.2024.0443","volume":"55","author":"J Lim","year":"2025","unstructured":"Lim J, Cho JY, Kwak S, Park CS, Park J, Choi HM, et al. Real-world experience of mavacamten for patients with obstructive hypertrophic cardiomyopathy in South Korea: a prospective multi-center observational study. Korean Circ J. 2025;55:339\u201354.","journal-title":"Korean Circ J"},{"key":"52_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1253\/circj.CJ-24-0501","volume":"89","author":"H Kitaoka","year":"2024","unstructured":"Kitaoka H, Ieda M, Ebato M, Kozuma K, Takayama M, Tanno K, et al. Phase 3 open-label study evaluating the efficacy and safety of mavacamten in Japanese adults with obstructive hypertrophic cardiomyopathy: the HORIZON-HCM study. Circ J. 2024;89:130\u20138.","journal-title":"Circ J"},{"key":"52_CR32","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","volume":"75","author":"CY Ho","year":"2020","unstructured":"Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;75:2649\u201360.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR33","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, et al. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med. 2024;390:1849\u201361.","journal-title":"N Engl J Med"},{"key":"52_CR34","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cardfail.2024.02.020","volume":"30","author":"A Masri","year":"2024","unstructured":"Masri A, Sherrid MV, Abraham TP, Choudhury L, Garcia-Pavia P, Kramer CM, et al. Efficacy and safety of aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4. J Card Fail. 2024;30:1439\u201348.","journal-title":"J Card Fail"},{"key":"52_CR35","doi-asserted-by":"publisher","first-page":"606","DOI":"10.4070\/kcj.2023.0035","volume":"53","author":"CS Park","year":"2023","unstructured":"Park CS, Rhee TM, Lee HJ, Yoon YE, Park JB, Lee SP, et al. Prognostic and safety implications of renin-angiotensin-aldosterone system inhibitors in hypertrophic cardiomyopathy: a real-world observation over 2,000 patients. Korean Circ J. 2023;53:606\u201318.","journal-title":"Korean Circ J"},{"key":"52_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/hrt.2011.227272","volume":"98","author":"IY Oh","year":"2012","unstructured":"Oh IY, Park KW, Kang SH, Park JJ, Na SH, Kang HJ, et al. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart. 2012;98:139\u201344.","journal-title":"Heart"},{"key":"52_CR37","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00228-010-0835-0","volume":"66","author":"M Ramsj\u00f6","year":"2010","unstructured":"Ramsj\u00f6 M, Aklillu E, Bohman L, Ingelman-Sundberg M, Roh HK, Bertilsson L, et al. CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. Eur J Clin Pharmacol. 2010;66:871\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"52_CR38","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023313","volume":"11","author":"C Tjahjadi","year":"2022","unstructured":"Tjahjadi C, Butcher SC, Zegkos T, Sia CH, Hirasawa K, Kamperidis V, et al. Differences in characteristics and outcomes between patients with hypertrophic cardiomyopathy from Asian and European centers. J Am Heart Assoc. 2022;11: e023313.","journal-title":"J Am Heart Assoc"},{"key":"52_CR39","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012441","volume":"18","author":"MY Desai","year":"2025","unstructured":"Desai MY, Seto D, Cheung M, Afsari S, Patel N, Bastien A, et al. Mavacamten: real-world experience from 22 months of the Risk Evaluation and Mitigation Strategy (REMS) Program. Circ Heart Fail. 2025;18: e012441.","journal-title":"Circ Heart Fail"},{"key":"52_CR40","unstructured":"McKeown LA. Mavacamten strikes out in phase III trial of nonobstructive HCM [Internet]. TCTMD; 2025 [cited 2025 Apr 23]. Available from: https:\/\/www.tctmd.com\/news\/mavacamten-strikes-out-phase-iii-trial-nonobstructive-hcm"},{"key":"52_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","volume":"81","author":"MS Maron","year":"2023","unstructured":"Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2023;81:34\u201345.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR42","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jacc.2009.04.026","volume":"54","author":"DH Kwon","year":"2009","unstructured":"Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol. 2009;54:242\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001002","volume":"3","author":"KC Siontis","year":"2014","unstructured":"Siontis KC, Geske JB, Ong K, Nishimura RA, Ommen SR, Gersh BJ, et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc. 2014;3: e001002.","journal-title":"J Am Heart Assoc"},{"key":"52_CR44","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","volume":"44","author":"E Braunwald","year":"2023","unstructured":"Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J. 2023;44:4622\u201333.","journal-title":"Eur Heart J"},{"key":"52_CR45","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jacbts.2022.04.008","volume":"7","author":"FI Malik","year":"2022","unstructured":"Malik FI, Robertson LA, Armas DR, Robbie EP, Osmukhina A, Xu D, et al. A phase 1 dose-escalation study of the cardiac myosin inhibitor aficamten in healthy participants. JACC Basic Transl Sci. 2022;7:763\u201375.","journal-title":"JACC Basic Transl Sci"},{"key":"52_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4250\/jcu.2015.23.1.20","volume":"23","author":"N Espinola-Zavaleta","year":"2015","unstructured":"Espinola-Zavaleta N, Vega A, Basto DM, Alcantar-Fern\u00e1ndez AC, GuarnerLans V, Soto ME, et al. Survival and clinical behavior of hypertrophic cardiomyopathy in a latin american cohort in contrast to cohorts from the developed world. J Cardiovasc Ultrasound. 2015;23:20\u20136.","journal-title":"J Cardiovasc Ultrasound"},{"key":"52_CR47","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jcmg.2024.08.005","volume":"18","author":"MY Desai","year":"2025","unstructured":"Desai MY, Okushi Y, Wolski K, Geske JB, Owens A, Saberi S, et al. Mavacamten-associated temporal changes in left atrial function in obstructive HCM: insights from the VALOR-HCM trial. JACC Cardiovasc Imaging. 2025;18:251\u201362.","journal-title":"JACC Cardiovasc Imaging"},{"key":"52_CR48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.124.017185","volume":"17","author":"MY Desai","year":"2024","unstructured":"Desai MY, Okushi Y, Gaballa A, Wang Q, Geske JB, Owens AT, et al. Serial changes in ventricular strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from the VALOR-HCM trial. Circ Cardiovasc Imaging. 2024;17: e017185.","journal-title":"Circ Cardiovasc Imaging"},{"key":"52_CR49","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/ehjci\/jeab187","volume":"23","author":"HJ Lee","year":"2022","unstructured":"Lee HJ, Kim HK, Lee SC, Kim J, Park JB, Hwang IC, et al. Supplementary role of left ventricular global longitudinal strain for predicting sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2022;23:1108\u201316.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"52_CR50","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.121.013556","volume":"15","author":"HJ Lee","year":"2022","unstructured":"Lee HJ, Kim HK, Rhee TM, Choi YJ, Hwang IC, Yoon YE, et al. Left atrial reservoir strain-based left ventricular diastolic function grading and incident heart failure in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2022;15: e013556.","journal-title":"Circ Cardiovasc Imaging"},{"key":"52_CR51","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4250\/jcvi.2022.0143","volume":"31","author":"S Kim","year":"2023","unstructured":"Kim S, Chung WJ. Longitudinal changes of left atrial volume index as a prognosticator in hypertrophic cardiomyopathy. J Cardiovasc Imaging. 2023;31:96\u20137.","journal-title":"J Cardiovasc Imaging"},{"key":"52_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4250\/jcvi.2022.0053","volume":"31","author":"K Kim","year":"2023","unstructured":"Kim K, Lee SD, Lee HJ, Kim H, Kim HR, Cho YH, et al. Role and clinical importance of progressive changes in echocardiographic parameters in predicting outcomes in patients with hypertrophic cardiomyopathy. J Cardiovasc Imaging. 2023;31:85\u201395.","journal-title":"J Cardiovasc Imaging"},{"key":"52_CR53","doi-asserted-by":"crossref","unstructured":"Kwak S, Kim J, Park CS, Lee HJ, Park JB, Lee SP, et al.\u00a0Prognostic implication of left ventricular global longitudinal strain in patients with hypertrophic cardiomyopathy and coexisting hypertension.\u00a0Korean Circ J.\u00a02025;","DOI":"10.4070\/kcj.2024.0213"},{"key":"52_CR54","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/heartjnl-2022-321853","volume":"109","author":"YJ Choi","year":"2023","unstructured":"Choi YJ, Kim HK, Hwang IC, Park CS, Rhee TM, Lee HJ, et al. Prognosis of patients with hypertrophic cardiomyopathy and low-normal left ventricular ejection fraction. Heart. 2023;109:771\u20138.","journal-title":"Heart"},{"key":"52_CR55","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/ehjdh\/ztae029","volume":"5","author":"KC Siontis","year":"2024","unstructured":"Siontis KC, Wieczorek MA, Maanja M, Hodge DO, Kim HK, Lee HJ, et al. Hypertrophic cardiomyopathy detection with artificial intelligence electrocardiography in international cohorts: an external validation study. Eur Heart J Digit Health. 2024;5:416\u201326.","journal-title":"Eur Heart J Digit Health"},{"key":"52_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100582","volume":"2","author":"KC Siontis","year":"2023","unstructured":"Siontis KC, Abreau S, Attia ZI, Barrios JP, Dewland TA, Agarwal P, et al. Patient-level artificial intelligence-enhanced electrocardiography in hypertrophic cardiomyopathy: longitudinal treatment and clinical biomarker correlations. JACC Adv. 2023;2: 100582.","journal-title":"JACC Adv"},{"key":"52_CR57","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jacasi.2023.12.001","volume":"4","author":"TM Rhee","year":"2024","unstructured":"Rhee TM, Ko YK, Kim HK, Lee SB, Kim BS, Choi HM, et al. Machine learning-based discrimination of cardiovascular outcomes in patients with hypertrophic cardiomyopathy. JACC Asia. 2024;4:375\u201386.","journal-title":"JACC Asia"},{"key":"52_CR58","doi-asserted-by":"crossref","unstructured":"Garcia-Pavia P, Bilen O, Burroughs M, Costabel JP, de Barros Correia E, Dybro AM, et al.\u00a0Aficamten vs. metoprolol for obstructive hypertrophic cardiomyopathy: MAPLE-HCM rationale, study design, and\u00a0baseline\u00a0characteristics.\u00a0JACC Heart Fail.\u00a02025;13:346\u201357.","DOI":"10.1016\/j.jchf.2024.11.011"},{"key":"52_CR59","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jamacardio.2024.3810","volume":"10","author":"SJ Shah","year":"2025","unstructured":"Shah SJ, Rigolli M, Javidialsaadi A, Patel RB, Khadra S, Goyal P, et al. Cardiac myosin inhibition in heart failure with normal and supranormal ejection fraction: primary results of the EMBARK-HFpEF trial. JAMA Cardiol. 2025;10:170\u20135.","journal-title":"JAMA Cardiol"}],"container-title":["Journal of Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44348-025-00052-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44348-025-00052-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44348-025-00052-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:02:52Z","timestamp":1751846572000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcvi.biomedcentral.com\/articles\/10.1186\/s44348-025-00052-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["52"],"URL":"https:\/\/doi.org\/10.1186\/s44348-025-00052-7","relation":{},"ISSN":["2586-7210","2586-7296"],"issn-type":[{"value":"2586-7210","type":"print"},{"value":"2586-7296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review article does not contain any studies with human participants and thus does not require approval from our institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.-K.K. is a consultant of BMS.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}